Niagen Bioscience (NAGE) Cash from Investing Activities (2011 - 2026)
Niagen Bioscience's (NAGE) quarterly Cash from Investing Activities came in at $5.2 million in Q1 2026, up 16490.62% year-on-year from N/an in Q1 2025, and up 5293.07% on a QoQ basis from -$101000.0 in Q4 2025.
Niagen Bioscience (NAGE) Cash from Investing Activities (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 14 years of Cash from Investing Activities data on file, last reported at $5.2 million in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 16490.62% year-over-year to $5.2 million in Q1 2026; TTM through Mar 2026 was $5.0 million, a 3820.15% increase from a year earlier, with the FY2025 full-year figure at -$292000.0, down 104.2% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $5.2 million, up from -$101000.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for NAGE reached as high as $5.2 million in Q1 2026 and fell as low as -$172000.0 in Q4 2022.
- Historically, Cash from Investing Activities has averaged $254882.4 across 5 years, with a median of -$32000.0 in 2025.
- Across the five-year window, Cash from Investing Activities tumbled 8500.0% in 2022 and soared 16490.62% in 2026, its largest moves.
- Year by year, Cash from Investing Activities stood at -$172000.0 in 2022, then soared by 87.79% to -$21000.0 in 2023, then slumped by 228.57% to -$69000.0 in 2024, then slumped by 46.38% to -$101000.0 in 2025, then soared by 5293.07% to $5.2 million in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were $5.2 million in Q1 2026, -$101000.0 in Q4 2025, and -$24000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Niagen Bioscience | 258.53 Mn | 191.98 Mn | 19.98 Mn | 5.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.25 Mn |
| Mar 31, 2026 | 5.25 Mn |
| Dec 31, 2025 | -101,000.00 |
| Dec 31, 2025 | -101,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Jun 30, 2025 | -135,000.00 |
| Jun 30, 2025 | -135,000.00 |
| Mar 31, 2025 | -32,000.00 |
| Mar 31, 2025 | -32,000.00 |
| Dec 31, 2024 | -69,000.00 |
| Dec 31, 2024 | -69,000.00 |
| Sep 30, 2024 | -21,000.00 |
| Sep 30, 2024 | -21,000.00 |
| Jun 30, 2024 | -12,000.00 |
| Jun 30, 2024 | -12,000.00 |
| Mar 31, 2024 | -41,000.00 |
| Mar 31, 2024 | -41,000.00 |
| Dec 31, 2023 | -21,000.00 |
| Dec 31, 2023 | -21,000.00 |